WAT Stock Analysis — Waters Corporation
Sector: Healthcare
AI Verdict
Waters trades at 23.8x next year's earnings with sky-high growth expectations, so you're getting a fair price for the sector only if their lab equipment moat delivers on the promised earnings surge.
Competitive Moat
Waters specializes in high-precision liquid chromatography and mass spectrometry instruments, which are mission-critical for pharmaceutical and life sciences labs. Their moat comes from deep integration into lab workflows and high switching costs due to proprietary consumables and software ecosystems.
Summary
A dramatic 100.5% forward EPS growth expectation is resetting the valuation narrative for this lab instrumentation supplier.
Where It Stands
Waters is up 7.81% over the past year, trades at 23.8x forward earnings (just above the healthcare median of 22x), and its RSI of 65.8 signals elevated pullback risk.
Key Metrics
- RSI: 65.8 — Near Overbought
- Trailing P/E: 47.8x
- Forward P/E: 23.8x
- PEG Ratio: 0.47
- Earnings Growth: +1.0%
- Revenue Growth: +0.3%
- Market Cap: $36.8B
- 1-Year Return: 7.81%
- 52-Week High: $414.15
- 52-Week Low: $275.05
Analyst Consensus
16 Buy · 14 Hold · 0 Sell (30 analysts)
Bull Case
With analysts expecting EPS to double (+100.5%) and the stock trading at 23.8x forward earnings, you're paying a reasonable multiple for explosive growth if it materializes.
Bear Case
If the forward P/E reverts to the sector median of 22x, that would mean a roughly 7.5% drop from current levels, and the 65.8 RSI suggests the stock could be due for a near-term pullback.
Catalyst to Watch
Watch for upcoming earnings to confirm whether the 100.5% EPS growth forecast is achievable, as a miss could trigger both a multiple and momentum reset.